Authors:
PRZEPIORKA D
KERNAN N
IPPOLITI C
PAPADOPOULOS E
GIRALT S
KHOURI I
LU J
GAJEWSKI J
DURETT A
CLEARY R
CHAMPLIN R
ANDERSSON B
LIGHT S
Citation: D. Przepiorka et al., PHASE-II STUDY OF DACLIZUMAB FOR TREATMENT OF ACUTE GRAFT-VS-HOST DISEASE, Experimental hematology, 26(8), 1998, pp. 35-35
Authors:
PORTER D
COLLINS R
MICK R
KERNAN N
GIRALT S
FLOWERS M
CASPER J
DROBYSKI W
LEAHEY A
PARKER P
BATES B
KING R
ANTIN J
Citation: D. Porter et al., UNRELATED DONOR LEUKOCYTE INFUSIONS (U-DLI) TO TREAT RELAPSE OR EBV-LYMPHOPROLIFERATIVE DISEASE (EBV-LPD) AFTER UNRELATED DONOR BONE-MARROWTRANSPLANTATION (BMT), Blood, 90(10), 1997, pp. 2622-2622
Authors:
AVIGAN D
PAPADOPOULOS E
BOULAD F
CASTROMALASPINA H
CHILDS B
MCKINNON S
GILLIO A
KERNAN N
SZABOLCS P
YOUNG J
OREILLY R
SMALL TN
Citation: D. Avigan et al., OPPORTUNISTIC INFECTIONS FOLLOWING RELATED AND UNRELATED T-CELL DEPLETED BONE-MARROW TRANSPLANTATION, Experimental hematology, 24(9), 1996, pp. 669-669
Authors:
MILBURN GL
CARRIGAN D
DIENGLEWICZ R
KERNAN N
PAPADOPOULOS E
SINGH N
Citation: Gl. Milburn et al., DIAGNOSIS OF ACTIVE HUMAN HERPESVIRUS-6 (HHV-6) INFECTIONS IN IMMUNOCOMPROMISED PATIENTS WITH A RAPID SHELL-VIAL ASSAY, Clinical chemistry, 42(6), 1996, pp. 127-127
Authors:
GARDNER S
BOULAD F
GILLIO A
KERNAN N
OREILLY R
SMALL T
SZABOLCS P
TAN C
GANSHAW L
VANSYCKLE K
MOSKOWITZ C
YAHALOM J
Citation: S. Gardner et al., HIGH-DOSE THERAPY WITH AUTOLOGOUS STEM-CELL RESCUE IN PEDIATRIC-PATIENTS WITH REFRACTORY HODGKINS-DISEASE, Blood, 88(10), 1996, pp. 481-481
Authors:
SMALL T
BOULAD F
KERNAN N
SZABOLCS P
VANSYCKLE K
PAPADOPOULOS E
BLACK P
TAYLOR J
CHILDS B
YOUNG J
CASTROMALASPINA H
JAKUBOWSKI A
OREILLY RJ
Citation: T. Small et al., ANALYSIS OF OPPORTUNISTIC INFECTIONS IN 423 PATIENTS FOLLOWING ALLOGENEIC UNMODIFIED OR T-CELL DEPLETED (TCD) RELATED OR UNRELATED BONE-MARROW TRANSPLANTATION, Blood, 88(10), 1996, pp. 1695-1695
Authors:
MCGLAVE P
KOLLMAN C
SHU XO
ANASETTI C
NADEMANEE A
CHAMPLIN R
ANTIN J
KERNAN N
KING R
Citation: P. Mcglave et al., THE FIRST 1000 UNRELATED DONOR TRANSPLANTS FOR CML - LESSONS FROM THENATIONAL MARROW DONOR PROGRAM (NMDP) EXPERIENCE, Blood, 88(10), 1996, pp. 1922-1922
Authors:
BOULAD F
GILLIO A
GARDNER S
KERNAN N
SMALL T
VANSYCKLE K
WILLIAMS T
YAHALOM J
OREILLY R
Citation: F. Boulad et al., ALLOGENEIC BONE-MARROW TRANSPLANTATION (ALLO-BMT) OR AUTOLOGOUS BMT (ABMT) FOR THE TREATMENT OF PEDIATRIC-PATIENTS WITH NON-HODGKINS-LYMPHOMA (NHL), Blood, 88(10), 1996, pp. 2458-2458
Authors:
PAPADOPOULOS EB
SMALL T
LADANYI M
BOULAD F
CASTROMALASPINA H
CHILDS B
KERNAN N
MACKINNON S
SZABOLCS P
YOUNG J
OREILLY RJ
Citation: Eb. Papadopoulos et al., CURRENT RESULTS OF DONOR LEUKOCYTE INFUSIONS (DLI) FOR TREATMENT OF EPSTEIN-BARR VIRUS-ASSOCIATED LYMPHOPROLIFERATIVE DISORDERS (EBVLPD) FOLLOWING RELATED AND UNRELATED T-CELL DEPLETED BONE-MARROW TRANSPLANT (TCDBMT), Blood, 88(10), 1996, pp. 2712-2712
Authors:
HOWE C
WAGNER J
KERNAN N
HURD D
BISHOP M
GINGRICH R
KURTZBERG J
CASPER J
HENSLEEDOWNEY J
PHILLIPS G
THOMPSON J
DONNENBERG A
LONG G
YANOVICH S
CARTERCAMPBELL S
Citation: C. Howe et al., T-CELL DEPLETION IN UNRELATED-DONOR MARROW TRANSPLANTATION, Blood, 86(10), 1995, pp. 1551-1551
Authors:
CASTROMALASPINA H
CHILDS B
LAVER J
SHANK B
BROCHSTEIN J
GILLIO A
FLOMENBERG N
YOUNG J
BOULAD F
BLACK P
KERNAN N
FUKS Z
OREILLY R
Citation: H. Castromalaspina et al., HYPERFRACTIONATED TOTAL LYMPHOID IRRADIATION AND CYCLOPHOSPHAMIDE FORPREPARATION OF PREVIOUSLY TRANSFUSED PATIENTS UNDERGOING HLA-IDENTICAL MARROW TRANSPLANTATION FOR SEVERE APLASTIC-ANEMIA, International journal of radiation oncology, biology, physics, 29(4), 1994, pp. 847-854
Authors:
CASTROMALASPINA H
CHILDS B
GILLIO A
PAPADOPOULOS E
BOULAD F
YOUNG J
SMALL T
MACKINNON S
KERNAN N
COLLINS N
REYES B
HELLER G
OREILLY R
Citation: H. Castromalaspina et al., BONE-MARROW TRANSPLANTATION FOR MYELODYSPLASTIC SYNDROMES AND SECONDARY ACUTE MYELOCYTIC-LEUKEMIA, Experimental hematology, 22(8), 1994, pp. 688-688
Authors:
BOULAD F
GILLIO A
SMALL T
BLACK P
KERNAN N
OREILLY RJ
Citation: F. Boulad et al., BONE-MARROW TRANSPLANTATION (BMT) FOR THE TREATMENT OF CHILDHOOD ACUTE MYELOGENOUS LEUKEMIA (AML) - THE MSKCC EXPERIENCE, Blood, 84(10), 1994, pp. 10000205-10000205